← Back to patent-cliff list
CAS 189441-63-2
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-15-[(tert-butyldimethylsilyl)oxy]-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate
Codes：(XLV)101438-35-c
Application context (from source-drug indications)
乳腺癌Paclitaxel/Encequidar mesylate腺癌Paclitaxel/Encequidar mesylate血管肉瘤Paclitaxel/Encequidar mesylate实体瘤Paclitaxel/Encequidar mesylate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Paclitaxel/Encequidar mesylatePaclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(1S,3S,5S,6R,7S,8S,10S,11S,13R,16S)-16-[(tert-butyldimethylsilyl)oxy]-8-chloro-7-hydroxy-7-(hydroxymethyl)-10-[(2-methoxypropan-2-yl)oxy]-11,15,18,18-tetramethyl-12-oxo-3-phenyl-2,4-dioxatetracyclo[12.3.1.0(1,5).0(6,11)]octadec-14-en-13-yl acetate→(1S,3S,5S,6R,7S,10R,12S,13S,15R,18S)-18-[(tert-butyldimethylsilyl)oxy]-7-hydroxy-12-[(2-methoxypropan-2-yl)oxy]-13,17,20,20-tetramethyl-14-oxo-3-phenyl-2,4,9-trioxapentacyclo[14.3.1.0(1,5).0(6,13).0(7,10)]icos-16-en-15-yl acetate→(1S,3S,5S,6R,7S,10R,12S,13S,15R,18S)-18-[(tert-butyldimethylsilyl)oxy]-7-hydroxy-13,17,20,20-tetramethyl-14-oxo-3-phenyl-12-[(triethylsilyl)oxy]-2,4,9-trioxapentacyclo[14.3.1.0(1,5).0(6,13).0(7,10)]icos-16-en-15-yl acetate→(1S,5S,6R,7S,10R,12S,13S,15R,18S)-18-[(tert-butyldimethylsilyl)oxy]-7-hydroxy-13,17,20,20-tetramethyl-3,14-dioxo-12-[(triethylsilyl)oxy]-2,4,9-trioxapentacyclo[14.3.1.0(1,5).0(6,13).0(7,10)]icos-16-en-15-yl acetate→(1S,5S,6R,7S,10R,12S,13S,15R,18S)-15-(acetyloxy)-18-[(tert-butyldimethylsilyl)oxy]-13,17,20,20-tetramethyl-3,14-dioxo-12-[(triethylsilyl)oxy]-2,4,9-trioxapentacyclo[14.3.1.0(1,5).0(6,13).0(7,10)]icos-16-en-7-yl acetate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-15-[(tert-butyldimethylsilyl)oxy]-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-15-[(tert-butyldimethylsilyl)oxy]-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-9-{[(2,2,2-trichloroethoxy)carbonyl]oxy}-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(2alpha,5beta,7beta,10beta,13alpha)-4,10-Bis(acetyloxy)-1,13-dihydroxy-9-oxo-7-[[(2,2,2-trichloroethoxy)carbonyl]oxy]-5,20-epoxytax-11-en-2-yl benzoate→2-Methoxy-1-propene→(1S,3S,5S,6S,8S,10S,11S,13R,16S)-16-[(tert-butyldimethylsilyl)oxy]-8-chloro-10-[(2-methoxypropan-2-yl)oxy]-11,15,18,18-tetramethyl-7-methylidene-12-oxo-3-phenyl-2,4-dioxatetracyclo[12.3.1.0(1,5).0(6,11)]octadec-14-en-13-yl acetate→(1S,3S,5S,6R,10S,11S,16S)-16-[(tert-butyldimethylsilyl)oxy]-10-[(2-methoxypropan-2-yl)oxy]-11,15,18,18-tetramethyl-12-oxo-3-phenyl-2,4-dioxatetracyclo[12.3.1.0(1,5).0(6,11)]octadeca-7,14-dien-7-yl trifluoromethanesulfonate→(1S,3S,5S,6S,10S,11S,16S)-16-[(tert-butyldimethylsilyl)oxy]-10-[(2-methoxypropan-2-yl)oxy]-11,15,18,18-tetramethyl-3-phenyl-7-[(trimethylsilyl)methyl]-2,4-dioxatetracyclo[12.3.1.0(1,5).0(6,11)]octadeca-7,14-dien-12-one→(1S,3S,5S,6S,8S,10S,11S,16S)-16-[(tert-butyldimethylsilyl)oxy]-8-chloro-10-[(2-methoxypropan-2-yl)oxy]-11,15,18,18-tetramethyl-7-methylidene-3-phenyl-2,4-dioxatetracyclo[12.3.1.0(1,5).0(6,11)]octadec-14-en-12-one→(1S,3S,5S,6S,8S,10S,11S,13S,16S)-16-[(tert-butyldimethylsilyl)oxy]-8-chloro-10-[(2-methoxypropan-2-yl)oxy]-11,15,18,18-tetramethyl-7-methylidene-12-oxo-3-phenyl-2,4-dioxatetracyclo[12.3.1.0(1,5).0(6,11)]octadec-14-en-13-yl acetate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.